|
Dr.Krishna
M.Ella
CMD, Bharat Biotech
International Ltd
"
Bio-entrepreneur "
City based Pharmaceutical
giant, Bharat Biotech has the second largest biotech plant facility in the world with a capacity to produce over 100 million doses of Hepatitis B
vaccine. It the first company in the world to perfect a technology that permits recovery of the Hepatitis B protein without the use of heavy metals and is also the First Biotech company awarded with two collaborative research grants from the Department of Science & Technology, Govt. of India.
The person heading this unique company is Dr.Krishna Ella,a Ph.D. from The University of Wisconsin, Madison and a M.S.,from The University of Hawaii.
Dr.Krishna Ella has also won a lot of Academic Awards such as the National Research Service
Award, Rotary Foundation (Chicago, Illinois) Fellowship, Indian
Council of Agri. Research Fellow, University Gold medallist
for highest C.G.P.A.,American Spring (ASPEE) Gold Medallist
and also bagged the Rotary International prize.
He has also been honoured with the 'Dr. K.C. Chatterjee Memorial Award' from the Indian Pharamaceutical Association, India in 1999.Had been the Member, National Task Force, Industrial Biotechnology in 1999.He was also the :Vice-President, All India Biotech Association, India(1999-2000).He is the Member- Pharma Task Force, Govt. of A.P
About Bharat Biotech International Limited:
Bharat Biotech International Limited was setup to carry out pioneering research and provide path-breaking solutions in the field of health care through Genetic Engineering.
Bharat Biotech crossed a major milestone in Biotechnology in October 1998, with the sensational development of REVAC-B, developed in Saccharomycea Cerevisiae.
The company has entered into the field of developing and manufacturing a vaccine for Hepatitis - B, Using a Recombinant DNA Technology route. Bharat Biotech is also seeking viable alternative remedies for diseases endemic to the Asian Region. The emphasis on developing the next generation of vaccine and drugs through original recombinant research to combat afflictions of the heart, pancreas, liver, kidney and nervous system.
An impressive state-of-art set up, built on a sprawling area of over 60,000 Sq.ft, with conditions completely controlled and conforming to the norms of the USFDA, UK , MCA and WHO specifications.
The strong and focused R&D personnel who are highly qualified and experienced professionals, possess remarkable expertise in the field of biotechnology, biochemistry, molecular biology, and industrial biotechnology and related fields. The high caliber team comprises of more than 30 leading scientists of repute. The dedicated team works in close collaboration with scientists and technologists belonging to the various collaboration scientific institutions
Every single test is conducted as per internationally recognized clinical and product quality protocol. This commitment to ethics is behind Bharat Biotech's distinction as the only company in India and the fourth in the world to use technology approved USFEA for the production of the Hepatitis B Vaccine, Revac B.
Scientists at Bharat Biotech together with those at Indian Institute of Science, Banglore and CBT - Delhi, are jointly working on future disease syndromes, which are region specific. The Universities in USA will rectify the quality of the products developed for certifying the results.
The Hepatitis B vaccine was launched in 1998 and ever since the capacity increased to cross 100 million doses per annum, perhaps the largest in the Asia Pacific region. Other products to treat heart attacks and diabetes are in various stages of development and will be introduced in due course. The clinical efficacy of the vaccine has been validated by human clinical trials in Multi Centric pattern. The data thus evolved proves that the vaccine is highly immunogenic in nature. Various new products developed at BBIL are undergoing clinical research in various parts of the world with internationally acceptable protocols, methods and Good Clinical Practices (GCP).
Bharat Biotech is the name to reckon with, in the Bio-Pharma industry. A relentless R&D efforts has established the company as a leading scientific and knowledge base institution of international repute.
Upgrading its R&D center to meet the challenges of the new millennium, the company is now in the process of strengthening its center in the campus of Indian Institute of Science.
Bangalore, into a full-fledged facility to undertake collaborative research and development. Key scientific collaborations with prestigious, premier, national and international research organizations and academic institutions
include: The Indian Institute of Science, Banglore,India The Center for Biochemical Technology,CSRI, New
Delhi, The Department of Science and Technology, Technology development Board.
-MK,
Hyderabad
|
